
Infectious disease doctor @UCSF. #LongCOVID researcher. #HIV clinician and #HIVcure researcher.
San Francisco, California
Joined March 2022
- Tweets88
- Following72
- Followers5.6K
- Likes13
Abstract deadline for 3rd International #LongCOVID Meeting is coming up - it is a privilege to be on the organizing committee and I am really looking forward to this meeting!
academicmedicaleducation.com…
Proud to have been a part of this @polybioRF effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.
BREAKING: Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID patients 💊
In a new report global experts outline key considerations to address persistent SARS-CoV-2; provide a roadmap to test critical new long COVID therapies: polybio.org/cutting-edge-rec…
New @UCSF #LIINC paper shows low mature/cytotoxic NK cells in #LongCovid compared to full recovery. Could reflect inability to clear infection. More interesting data showing immunologic differences in #LongCovid. Thanks to @polybioRF @NIH for funding.
jci.org/articles/view/188182
Excited to share this @ScienceTM viewpoint with @DrMaureenHanson on why #LongCOVID #MECFS and other infection-associated chronic conditions should be studied together as part of a coordinated research agenda.
science.org/doi/10.1126/scit…
Lots of attention on cortisol in #LongCovid lately. Here are results from a pilot project in the @UCSF #LIINC cohort. Similar levels between LC and recovered, but morning dynamics appear to differ, esp. in those with post-COVID ME/CFS. Detailed follow up project ongoing.
Realizing I forgot the link which is here: medrxiv.org/content/10.1101/…
New @CMIJournal study showing association between post-acute SARS-CoV-2 protein in blood and #LongCOVID. Data from 4 cohorts, including #NIHRECOVER and @UCSF #LIINC. Need more research ASAP to see if useful as a biomarker for trials!
Michael Peluso, MD retweeted
Long Covid Research 💰💰
In our @NatureIndex piece, @MichaelPelusoMD & I expound on different funding avenues for #brainfog…and the dire need for science + answers.
Thx to @BecCrew for her wisdom & insight as editor.
Read here:
go.nature.com/3NgBcC4
Excited to be visiting @VirusesImmunity at the 2nd @YaleCII symposium today to talk about #LongCovid - Where we are, where we need to go, and how we can get there.
Excellent commentary from @patientled in Cell outlining priorities for #LongCOVID research.
sciencedirect.com/science/ar…
Our mechanistic review of #LongCovid - published in @CellCellPress - hopefully will be helpful coming out of the very inspiring RECOVER-Treating Long COVID meeting this week.
Excited for the progress we will make together in the next year!
sciencedirect.com/science/ar…
Our new @UCSF #FindCOVID/#LIINC paper in @NatureComms showing SCV2 burden in first 3 weeks of COVID predicts future #LongCovid.
In addition to LC treatment trials, we need investment in studies to prevent LC! Zero US-based trials on prevention so far.
nature.com/articles/s41467-0…
Michael Peluso, MD retweeted
Today, we are thrilled to see the introduction of The Long COVID Research Moonshot Act by Senator Bernie Sanders (@SenSanders), co-sponsored by Senators @SenTimKaine, @SenDuckworth, @SenMarkey, @SenPeterWelch, and @SenTinaSmith!
sanders.senate.gov/wp-conten…
#LongCovid 1/
Michael Peluso, MD retweeted
Breaking!: Research published today in Science Translational Medicine and supported by PolyBio Research Foundation shows that the #SARS-CoV-2 virus can chronically persist in the gut of patients with long COVID for over 2 years: polybio.org/chronic-virus-fo…
New @UCSF #LIINC paper: immune activation & viral persistence in tissue up to 2 years post-COVID. Found double-stranded RNA in #LongCOVID, suggesting active reservoir persists and evades immune clearance. Thanks @polybioRF, @NIH for support. @ScienceTM
science.org/doi/10.1126/scit…
Today, the #Stanford #Paxlovid trial for #LongCOVID (STOP-PASC) reported no difference in patient reported outcomes between drug vs placebo.
Headlines say it's "negative," some are saying we should abandon the virus persistence hypothesis. My take:
jamanetwork.com/journals/jam…
7) This was not a home run. But a great rally (and a big win) often starts with getting the leadoff hitter onto first - putting the rest of the lineup in position to build on that success. Science is the same way - early base hits eventually get you a win by building momentum.














